Author

O. Kauko

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Organism:human· 3 Assay:proteomics· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Research Focus:drug response / drug discovery· 2 Approach:statistical model· 2

Frequent Co-Authors

J. Westermarck· 3 shared A. Kaur· 2 shared M. Paakkonen· 2 shared A. Aakula· 1 shared A. Erickson· 1 shared A. Hakkinen· 1 shared A. Isomursu· 1 shared A. Murgia· 1 shared

Activity by Year

2019-2022 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 26 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

J. Westermarck

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Lineage-specific oncogenes drive growth of major forms of human cancer using common downstream mechanisms

O. Kauko, M. Turunen, P. Pihlajamaa, A. Hakkinen, R. M. Queiroz, M. Paakkonen, S. Ventela, M. Gaetani, S. Lundstrom, A. Murgia, B. Sahu, J. Routila, H. Irjala, J. L. Griffin, K. S. Lilley, , J. Taipale

The paper identifies common downstream mechanisms driven by lineage-specific oncogenes that regulate cell proliferation in various cancers.

bioRxiv · Sep 27, 2022 · PreprintCancer Biology

Pharmacological PP2A reactivation overcomes multikinase inhibitor tolerance across brain tumor cell models

O. Denisova, J. Merisaari, R. Huhtaniemi, X. Qiao, A. Kaur, L. Yetukuri, M. Jumppanen, M. Paakkonen, C. von Schantz-Fant, M. Ohlmeyer, K. Wennerberg, O. Kauko, R. Koch, T. Aittokallio, M. Taipale, J. Westermarck

This study identifies a triplet therapy combining AKT, PDK1-4 inhibition, and PP2A reactivation that effectively eradicates brain tumor models by overcoming kinase inhibitor tolerance through combinatorial effects on signaling rewiring, OXPHOS, and apoptosis.

bioRxiv · May 31, 2022 · PreprintCancer Biology

PME-1 suppresses anoikis, and is associated with therapy relapse of PTEN-deficient prostate cancers

A. Aakula, A. Isomursu, C. Rupp, A. Erickson, O. Kauko, P. Shah, A. Padzik, Y. R. Pokharel, A. Kaur, S.-P. Li, L. Trottman, P. Taimen, A. Rannikko, J. Lammerding, I. Paatero, , J. Westermarck

This study identifies PME-1 as a biomarker for aggressive PTEN-deficient prostate cancers by showing its role in suppressing anoikis.

bioRxiv · Mar 17, 2022 · PreprintCancer Biology

ARPP19 promotes MYC expression and associates with patient relapse in acute myeloid leukemia

E. Makela, E. Loyttyniemi, U. Salmenniemi, O. Kauko, T. Varila, V. Kairisto, M. Itala-Remes, J. Westermarck

This study identifies ARPP19 as an oncogenic PP2A inhibitor in AML that predicts relapse independently of risk classification and is associated with disease activity.

bioRxiv · Jul 5, 2019Cancer Biology